Abstract:Background The beneficial effects of the neuregulin/ErbB pathway on the diseased heart have been well-established. The anti-fibrotic and cardioprotective aspects of neuregulin are largely attributable to the activation of the ErbB4 receptor. We recently developed a small-molecule selective ErbB4 agonist, which reduced collagen production in cultured fibroblasts and prevented oxidative-stress induced cardiomyocyte death in vitro. Purpose In order to evaluate the in vivo effects of this small-molecule ErbB4 agonist (referred to as compound, Cpd), we assessed its effect on left ventricular remodelling, cardiac fibrosis and cardiac function in a murine model of myocardial infarction (MI). Since there is a potential interaction between ErbB4 and the oestrogen receptor, we also aimed to evaluate whether these effects were sex-dependent. We hypothesised that Cpd would attenuate left ventricular remodelling, reduce cardiac fibrosis and help retain cardiac function in a sex-specific manner. Methods Mice were divided by sex and then further divided into three experimental groups: a sham group, an MI group receiving Cpd (MI/Cpd), and a control MI group receiving vehicle only (MI/Veh). MI was induced by ligating the left descending coronary artery. Seven days after MI, mice started treatment with either Cpd (2mg/kg/d) or its vehicle through subcutaneous osmotic minipumps. Cardiac ultrasound was performed weekly until mice were sacrificed after four weeks of treatment. Hearts were excised and stained with Masson's trichrome to assess reactive cardiac fibrosis in the myocardium of the left ventricle, located remote from the infarction scar. A WGA-isolectinB4-DAPI immunofluorescent stain was performed to assess cardiomyocyte cross-sectional area in order to evaluate cardiomyocyte hypertrophy. Results In females (n=25), Cpd significantly decreased left ventricular end-diastolic volume compared to vehicle (LVEDV, Fig.1A, 80±23 μl vs.108±29 μl, p=0.045) and induced a slightly increased left ventricular ejection fraction (LVEF, Fig.1B, 32±12% vs. 22±9%, p=0.086). In addition, Cpd significantly reduced reactive interstitial fibrosis myocardium (Fig.1C, fibrotic area, 1.4±1.0% vs. vehicle: 3.8±3.1%, p=0.0363). In males (n=30), Cpd had no significant effects on either of the parameters mentioned above, (Fig.1E-G). There was no significant treatment effect in either group on cardiomyocyte cross sectional area (Fig.1D, Fig.1H). Conclusion Treatment with the novel small-molecule ErbB4 agonist attenuates left ventricular dilation and reactive interstitial fibrosis after MI in female mice, but not in males. These data support the premise that small molecule-induced ErbB4 activation is a potential new therapy for heart failure, especially in female patients. The mechanisms underlying the sex-dependent effects warrant further exploration.Figure 1

Cardiomyocyte-specific Overexpression of Estrogen Receptor Alpha Promotes Angiogenesis and Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart after Myocardial Infarction

Estrogen Induces Cardioprotection in Male C57bl/6j Mice after Acute Myocardial Infarction Via Decreased Activity of Matrix Metalloproteinase-9 and Increased Akt-Bcl-2 Anti-Apoptotic Signaling

Endothelial estrogen - myocardial cGMP axis critically determines angiogenesis and cardiac performance during pressure-overload

Effects of Estrogen on Cardiac mRNA and LncRNA Expression Profiles in Hypertensive Mice

Estrogen-replacement Therapy Promotes Angiogenesis after Acute Myocardial Infarction by Enhancing SDF-1 and Estrogen Receptor Expression.

17Β-Estradiol Promotes Recovery after Myocardial Infarction by Enhancing Homing and Angiogenic Capacity of Bone Marrow-Derived Endothelial Progenitor Cells Through ERα-SDF-1/CXCR4 Crosstalking.

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy

A newly developed small-molecule ErbB4 agonist reduces reactive cardiac fibrosis and adverse ventricular remodelling after myocardial infarction in a sex-specific manner

G Protein-Coupled Estrogen Receptor 1 Mediates Acute Estrogen-Induced Cardioprotection via MEK/ERK/GSK-3β Pathway after Ischemia/Reperfusion

Abstract 9682: The Cardiac Protective Effects of Novel Synthetic Pan-Estrogen Related Receptor Agonists Slu-pp-332 and Slu-pp-915

17β-Oestradiol facilitates M2 macrophage skewing and ameliorates arrhythmias in ovariectomized female infarcted rats

Acute activation of G protein-coupled estrogen receptor induces cardioprotective effects against myocardial ischemia reperfusion injury in male and female ovariectomized rats

Abstract 528: Endothelial Estrogen Receptor Alpha Deletion Promotes Abdominal Aortic Aneurysm In Male Mice

Estrogen mediated regulation of TGFβ pathway signaling in cardiac hypertrophy (795.4)

Downregulation of miR-151-5p contributes to increased susceptibility to arrhythmogenesis during myocardial infarction with estrogen deprivation

Abstract 12559: Chronic GPER Activation Attenuates Cardiac Dysfunction in a Male Mouse Model of Progressive Heart Failure: Insights Into Cellular Mechanisms

Estradiol Ameliorates Acute Kidney Ischemia-Reperfusion Injury by Inhibiting the TGF-βRI-SMAD Pathway

Abstract 408: An Essential Protective Role for Cardiomyocyte Alpha1a-adrenergic Receptors in a Mouse Model of Myocardial Infarction

Sexually Dimorphic Adaptation of Cardiac Function: Roles of Epoxyeicosatrienoic Acid and Peroxisome Proliferator-Activated Receptors

17Β-Estradiol Enhances the Recruitment of Bone Marrow-Derived Endothelial Progenitor Cells into Infarcted Myocardium by Inducing CXCR4 Expression

Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats